CHS-1420

· Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CHS-1420, covering 2019-10-18 to 2026-01-09. Get the full timeline:

Most recent: Clinical Trial Update: A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions [Phase 1]

See pricing